Vineet Laboratories Ltd

Vineet Laborator Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vineet Laboratories Ltd

₹ 33.0 1.16%
08 Jul 4:01 p.m.
vineetlabs.co.in BSE: 543298 NSE: VINEETLAB
About

Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs

Key Points

Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.

Website BSE NSE - BE
  • Market Cap ₹ 30.4 Cr.
  • Current Price ₹ 33.0
  • High / Low ₹ 78.5 / 25.4
  • Stock P/E
  • Book Value ₹ 15.9
  • Dividend Yield 0.00 %
  • ROCE -25.1 %
  • ROE -81.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • Promoter holding is low: 35.8%
  • Company has a low return on equity of -19.6% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
56 49 40 67 57 38 43 33 37 24 19 18 14
50 45 44 65 51 37 39 33 34 25 19 22 25
Operating Profit 6 4 -4 2 6 0 4 -1 3 -1 -0 -4 -11
OPM % 11% 8% -10% 3% 10% 1% 10% -2% 9% -3% -2% -23% -78%
0 0 0 0 0 0 0 0 0 0 0 0 1
Interest 1 1 1 1 0 1 1 1 2 1 1 1 1
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 5 2 -5 0 5 -1 3 -2 1 -2 -2 -6 -11
Tax % 32% 52% -12% -239% 27% -2% 5% -11% -34% -2% 7% 1% -6%
3 1 -5 1 4 -1 2 -2 2 -2 -2 -6 -11
EPS in Rs 3.56 1.10 -5.10 1.51 3.85 -1.36 2.63 -2.25 2.08 -2.31 -1.99 -6.19 -11.42
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 243 191 212 151 75
0 235 178 205 143 91
Operating Profit -0 8 13 8 7 -16
OPM % 3% 7% 4% 5% -22%
0 0 0 0 0 2
Interest 0 3 2 3 5 4
Depreciation 0 2 2 2 3 2
Profit before tax -0 4 9 2 0 -21
Tax % 0% 56% 29% 38% -183% -3%
-0 2 7 1 1 -20
EPS in Rs -0.24 1.93 7.20 1.36 1.12 -21.90
Dividend Payout % 0% 0% 14% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -27%
TTM: -50%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -2656%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -18%
1 Year: -47%
Return on Equity
10 Years: %
5 Years: -7%
3 Years: -20%
Last Year: -82%

Balance Sheet

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.41 9 9 9 9 9
Reserves -0 17 24 24 26 5
0 12 27 31 44 40
0 70 74 51 38 40
Total Liabilities 0 109 133 116 117 95
0 20 21 27 27 25
CWIP 0 0 0 0 0 0
Investments 0 0 0 0 0 0
0 89 112 89 90 69
Total Assets 0 109 133 116 117 95

Cash Flows

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 27 8 -10 -11 11
0 -8 -4 -7 0 -3
0 19 12 0 11 -8
Net Cash Flow 0 38 16 -16 -0 0

Ratios

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 64 69 60 77 64
Inventory Days 73 109 98 158 260
Days Payable 114 161 74 103 175
Cash Conversion Cycle 23 17 84 131 150
Working Capital Days 28 28 66 126 139
ROCE % 34% 23% 9% 7% -25%

Shareholding Pattern

Numbers in percentages

33 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
35.96% 35.96% 35.96% 38.66% 38.66% 38.66% 37.55% 37.50% 37.50% 36.07% 35.85% 35.85%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.24% 0.00% 0.00% 0.00% 0.00% 0.00%
64.04% 64.04% 64.03% 61.35% 61.34% 61.34% 62.20% 62.50% 62.49% 63.93% 64.15% 64.15%
No. of Shareholders 9,5789,4369,5279,8219,3069,4699,5149,6389,52310,30010,05810,025

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports